Balanced news tone
News Sentiment
AURA sentiment intelligence
Aura Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
-11.6% over one week, +6.7% over four weeks, trend active, and near fair-value range.
Aura Minerals bounces back from recent drop with 7% advance (AUGO:NASDAQ)
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Aura Biosciences Completes Enrollment in Phase 3 Trial of Belzupacap Sarotalocan for Early Choroidal Melanoma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:39
- Source
- MT Newswires
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jun 2026 12:00
- Source
- GlobeNewswire
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 20:04
- Source
- MarketBeat
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 May 2026 02:02
- Source
- MarketBeat
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 May 2026 20:50
- Source
- GlobeNewswire
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Aura Biosciences to Participate in Upcoming Investor Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 May 2026 20:01
- Source
- GlobeNewswire
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 20:01
- Source
- GlobeNewswire
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 May 2026 21:15
- Source
- GlobeNewswire
Aura Biosciences Prices $260 Million Stock Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 14:19
- Source
- MT Newswires
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Market source
Aura Biosciences Inc. Announces Pricing of $260.3 Million Public Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Quiver Quantitative
Aura Biosciences Announces CEO Transition as Company
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- GlobeNewswire
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Mar 2026 07:00
- Source
- Market source
Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 26 Nov 2025 08:00
- Source
- simplywall.st
Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 May 2025 07:00
- Source
- GlobeNewswire